We would like to clarify that, in the June 16 issue of Marketletter reporting fiscal 2007/8 results for UK-based Protherics, the L10.0 million milestone received from AstraZeneca applied to the previous financial year. Also, Protherics will regain rights to both DigiFab and CroFab in 2010. We apologize for any confusion this may have caused.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze